Stocklytics Platform
Asset logo for symbol ELVN
Enliven Therapeutics, Inc. - Common Stock
High Growth
Asset logo for symbol ELVN



Income Statement (ELVN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
gross Profit-$79.00K$363.00K-$79.00K-$74.00K-$67.00K
NET Income-$22.73M-$19.37M-$20.76M-$16.72M-$13.03M
total Revenue$0.00$440.00K$0.00$0.00$0.00

Balance Sheet (ELVN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$148.96M-$99.86M-$73.51M-$125.38M-$291.77M
stockholders Equity$317.71M$245.90M$261.74M$278.99M$291.41M
total Assets$342.77M$271.86M$274.04M$288.50M$302.86M
total Debt$252.00K$335.00K$332.00K$329.00K$326.00K
total Liabilities$25.06M$25.96M$12.29M$9.50M$11.45M

Cash Flow (ELVN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$90.27M$90.00K-$425.00K-$2.82M$237.44M
free Cash Flow-$23.38M-$12.49M-$15.91M-$12.13M-$20.87M
investing Cash Flow----$151.51M-$31.00K
operating Cash Flow-$23.36M-$12.48M-$15.89M-$12.04M-$20.84M

Enliven Therapeutics, Inc. - Common Stock (ELVN) Financials

Enliven Therapeutics, Inc. is a publicly traded company that offers common stock (ticker symbol: ELVN) to investors. As a pharmaceutical company, Enliven Therapeutics focuses on the development and commercialization of innovative therapeutic solutions. In order to provide transparency to its shareholders and potential investors, the company regularly releases its financial statements. These financials offer a comprehensive view of Enliven Therapeutics' performance and financial health.

The income statement is one of the key financial statements that Enliven Therapeutics discloses. This statement provides information on the company's revenues, expenses, and profits over a specific period of time. It helps investors understand the profitability of the company and its ability to generate income. Similarly, the gross profit reveals the profit remaining after subtracting the cost of goods sold from total revenue. This metric is important in assessing the efficiency of Enliven Therapeutics' operations.

Another essential metric is the EBIT (Earnings Before Interest and Taxes). EBIT indicates the company's operating profit before considering interest expenses and income taxes. It helps investors measure the company's profitability without the influence of financing decisions and tax considerations. Additionally, EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a financial indicator that provides an even broader picture of Enliven Therapeutics' profitability by excluding non-cash expenses like depreciation and amortization.

Enliven Therapeutics' net income from stockholders shows the profitability available for common stockholders after all expenses, interest, and taxes. This figure gives insight into the dividends or reinvestment potential for shareholders. Moreover, the balance sheet presents the company's financial position at a specific point in time. It reveals Enliven Therapeutics' assets, liabilities, and stockholders' equity. Investors can assess the company's liquidity, solvency, and financial stability through this statement.

The key components of Enliven Therapeutics' balance sheet include total assets, total liabilities, and stockholders' equity. Total assets represent the value of resources owned by the company, which could include tangible assets like property and equipment, as well as intangible assets like patents and trademarks. On the other hand, liabilities encompass the company's obligations or debts. Stockholders' equity represents the residual interest in the assets of the company after deducting liabilities.

In terms of cash flow, Enliven Therapeutics' operating cash flow provides insight into the net cash generated from the company's core operations. This metric is crucial in evaluating the company's ability to generate cash and sustain its operations. Additionally, the investing cash flow reveals the company's cash inflows and outflows related to investments in long-term assets, such as property, plant, and equipment. The financing cash flow highlights the cash flows associated with raising capital or repaying debts.

Furthermore, Enliven Therapeutics' free cash flow represents the cash generated by the company after accounting for capital expenditures necessary to maintain or expand its asset base. This metric is useful in determining the company's financial flexibility and its capacity to reward shareholders through dividends or share repurchases. Lastly, the cash equivalents represent highly liquid assets held by Enliven Therapeutics that can be readily converted into cash.

In conclusion, Enliven Therapeutics, Inc. provides comprehensive financial information through its income statement, balance sheet, and cash flow statement. These financials allow investors to assess the company's financial performance, profitability, liquidity, and overall financial health. Proper analysis of these metrics can help investors make informed decisions regarding investment in Enliven Therapeutics' common stock (ELVN).

add Enliven Therapeutics, Inc.  - Common Stock to watchlist

Keep an eye on Enliven Therapeutics, Inc. - Common Stock

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level